Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 8/20 | 0.38 |
| ▸ | CDK4 | P11802 | 1/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | CCND1 | P24385 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.37 |
| ▸ | CTSD | P07339 | 4/20 | 0.37 |
| ▸ | GRB2 | P62993 | 1/20 | 0.35 |
| ▸ | ACE | P12821 | 2/20 | 0.35 |
| ▸ | CTSB | P07858 | 3/20 | 0.35 |
| ▸ | CTSK | P43235 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13363654 | 0.84 | ACE (0.49) | RENGRB2ACE | |
| SCHEMBL29641501 | 0.81 | CTSD (0.44) | RENCTSD | |
| SCHEMBL10431112 | 0.81 | REN (0.48) | RENCTSDACE | |
| SCHEMBL30684922 | 0.80 | CTSD (0.44) | RENCTSDCTSBCTSK | |
| SCHEMBL16359592 | 0.77 | ACE (0.39) | GRB2ACE | |
| SCHEMBL30799828 | 0.77 | ENPEP (0.40) | RENCTSDGRB2ACE | |
| SCHEMBL31318666 | 0.77 | ENPEP (0.41) | ACE | |
| SCHEMBL30434077 | 0.77 | CTSD (0.42) | RENCCNA2CDK2CCNA1CTSD | |
| SCHEMBL11012174 | 0.77 | ACE (0.43) | RENCDK4CCNA2CCND1CDK2 | |
| SCHEMBL30684916 | 0.76 | LNPEP (0.42) | ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7927581-B2 | For magnetic resonance imaging (MRI); peptide modified at its N- and its C-termini, independently, with a moiety comprising a metal chelate complex; specific binding affinity for fibrin; sufficient half-life in vivo | Factor 1A, LLC (US) | 2011-04-19 | — | — | US | disclosed |
| US-7927581-B2 | For magnetic resonance imaging (MRI); peptide modified at its N- and its C-termini, independently, with a moiety comprising a metal chelate complex; specific binding affinity for fibrin; sufficient half-life in vivo | Factor 1A, LLC (US) | 2011-04-19 | — | — | US | disclosed |
| US-20060039861-A1 | Peptide-based multimeric targeted contrast agents | EPIX MEDICAL, INC., A DELAWARE CORPORATION | 2006-02-23 | — | — | US | disclosed |
| US-20060039861-A1 | Peptide-based multimeric targeted contrast agents | EPIX MEDICAL, INC., A DELAWARE CORPORATION | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060039861-A1 | Peptide-based multimeric targeted contrast agents | NGLY1, IAPP, NPPA | REN 1854/4885CDK4 4125/4885CCNA2 3665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.